Phyto-Therapeutic and Nanomedicinal Approaches to Cure Alzheimer’s Disease: Present Status and Future Opportunities
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is characterized by cognitive inability manifested due to the accumulation of β-amyloid, formation of hyper phosphorylated neurofibrillary tangles, and a malfunctioned cholinergic system. The degeneration integrity of the neuronal network can appear long after the onset of the disease. Nanotechnology-based interventions have opened an exciting area via theranostics of AD in terms of tailored nanomedicine, which are able to target and deliver drugs across the blood-brain barrier (BBB). The exciting interface existing between medicinal plants and nanotechnology is an emerging marvel in medicine, which has delivered promising results in the treatment of AD. In order to assess the potential applications of the medicinal plants, their derived components, and various nanomedicinal approaches, a review of literature was deemed as necessary. In the present review, numerous phytochemicals and various feats in nanomedicine for the treatment of AD have been discussed mechanistically for the first time. Furthermore, recent trends in nanotechnology such as green synthesis of metal nanoparticles with reference to the treatment of AD have been elaborated. Foreseeing the recent progress, we hope that the interface of medicinal plants and nanotechnology will lead to highly effective theranostic strategies for the treatment of AD in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063 · cited 2×
“The aforementioned events Frontiers in Aging Neuroscience | www.frontiersin.org 1 October 2018 | Volume 10 | Article 284 thus, lead to the degenerative diseases like AD and dementia (Selkoe, 2001).”
BackgroundStructure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185
Daneman, R., & Prat, A. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020412 · Cited by 3,437
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499 · cited 1×
“…clinical symptoms of AD patients include impairment in memory, e.g., current conversations, names or events, while later symptoms comprises poor communication, misperception, confusion, misjudgment, changed attitude, and finally, difficulty in speaking, swallowing, and walking (Khachaturian, 1985).”
BackgroundYang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Cited by
Biosynthesis of Metal Nanoparticles via Microbial Enzymes: A Mechanistic Approach
Ovais, M., Khalil, A. T., Ayaz, M., Ahmad, I., Nethi, S. K., & Mukherjee, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19124100 · Cited by 475
Self-citationAyaz, M., Ullah, F., Sadiq, A., Ullah, F., Ovais, M., Ahmed, J., & Devkota, H. P. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.05.050 · Cited by 359
Self-citationPatil, S., & Chandrasekaran, R. (2020) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-020-00081-3 · Cited by 347
Ayaz, M., Sadiq, A., Junaid, M., Ullah, F., Ovais, M., Ullah, I., Ahmed, J., & Shahid, M. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00155 · Cited by 320
Self-citationApplications of Phyto-Nanotechnology for the Treatment of Neurodegenerative Disorders
Bhattacharya, T., Soares, G. A. B. E., Chopra, H., Rahman, M. M., Hasan, Z., Swain, S. S., & Cavalu, S. (2022) · Materials · doi:10.3390/ma15030804 · Cited by 259
Mohd Sairazi, N. S., & Sirajudeen, K. N. S. (2020) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2020/6565396 · Cited by 237
Neuroprotective Natural Products for Alzheimer’s Disease
Chen, X., Drew, J., Berney, W., & Lei, W. (2021) · Cells · doi:10.3390/cells10061309 · Cited by 236
Rahman, M. H., Bajgai, J., Fadriquela, A., Sharma, S., Trinh, T. T., Akter, R., Jeong, Y. J., Goh, S. H., Kim, C.-S., & Lee, K.-J. (2021) · Molecules · doi:10.3390/molecules26175327 · Cited by 182
Biswas, D., Mandal, S., Chatterjee Saha, S., Tudu, C. K., Nandy, S., Batiha, G. E., Shekhawat, M. S., Pandey, D. K., & Dey, A. (2021) · Phytotherapy Research · doi:10.1002/ptr.7248 · Cited by 83
La Barbera, L., Mauri, E., D’Amelio, M., & Gori, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.939855 · Cited by 74
Abduljawad, A. A., Elawad, M. A., Elkhalifa, M. E. M., Ahmed, A., Hamdoon, A. A. E., Salim, L. H. M., Ashraf, M., Ayaz, M., Hassan, S. S. U., & Bungau, S. (2022) · Molecules · doi:10.3390/molecules27206804 · Cited by 63
“The Aβ plaques are considered to be responsible for the pathogenesis of AD (amyloid hypothesis) [22,23].”
BackgroundSelf-citationMetal Nanoparticles in Alzheimer’s Disease
Behera, A., Sa, N., Pradhan, S. P., Swain, S., & Sahu, P. K. (2023) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-220112 · Cited by 50
Metadata
- Authors
- Ovais, M., Zia, N., Ahmad, I., Khalil, A. T., Raza, A., Ayaz, M., Sadiq, A., Ullah, F., & Shinwari, Z. K.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2018-10-23
- Volume
- 10
- Pages
- 284-284
- ISSN
- 1663-4365 (ISSN-L)
- OpenAlex
- W2896526587
- Cited by
- 138
- References
- 56
- FWCI
- 17.03
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.